Results 121 to 130 of about 114,228 (331)

Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease.

Cochrane Database of Systematic Reviews, 2006
G. Strippoli, C. Bonifati, M. Craig, S. Navaneethan, J. Craig   +4 more
semanticscholar   +1 more source

The effects of sodium–glucose cotransporter 2 inhibitors on the ‘forgotten’ right ventricle

ESC Heart Failure, Volume 12, Issue 2, Page 1045-1058, April 2025.
Abstract With the progress in diagnosis, treatment and imaging techniques, there is a growing recognition that impaired right ventricular (RV) function profoundly affects the prognosis of patients with heart failure (HF), irrespective of their left ventricular ejection fraction (LVEF).
Liangzhen Qu, Xueting Duan, Han Chen
wiley   +1 more source

Angiotensin II receptor antagonists – we have moved closer to the patient

Кардиоваскулярная терапия и профилактика, 2005
Aim. To investigate antihypertensive efficacy of losartan (Lozap®), as monotherapy and in combination with a diuretic hydrochlorothiazide (Lozap® Plus), according to its influence on circadian blood pressure profile (CBPP) in patients with arterial ...
L. G. Ratova, I. P. Kolos, I. E. Chazova
doaj  

Role of Angiotensin II Receptor Antagonists in Hipertensión

, 2014
Role of Angiotensin II Receptor Antagonists in Hipertensió
de la Parte, María, Hernández Hernández, Rafael, Velasco, Manuel, Hernández, María José, Armas, María C.   +4 more
core  

Síntese de potenciais antagonistas do receptor b1 da bradicinina contendo o heterociclo dihidropiridazinona [PDF]

, 2010
TCC (graduação) - Universidade Federal de Santa Catarina, Centro de Ciências Físicas e Matemáticas, Curso de Química.Com base nas estruturas de seletivos antagonistas não peptídicos do receptor B1 da bradicinina, foram desenvolvidos novos análogos ...
Maximiano, Adrielle Patricio
core  

Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review

British medical journal, 2004
G. Strippoli, M. Craig, J. Deeks, F. Schena, J. Craig   +4 more
semanticscholar   +1 more source

Implementation of guideline‐recommended medical therapy for patients with heart failure in Europe

ESC Heart Failure, Volume 12, Issue 2, Page 790-798, April 2025.
Abstract Physicians' adherence to guideline‐recommended heart failure (HF) treatment remains suboptimal, especially regarding the target doses. In particular, there is evidence that non‐cardiologists are less compliant with HF guideline recommendations. This is likely to have a detrimental impact on patients' survival, readmissions and quality of life.
Maurizio Volterrani, Petar Seferovic, Gianluigi Savarese, Ilaria Spoletini, Egidio Imbalzano, Antoni Bayes‐Genis, Ewa Jankowska, Michele Senni, Marco Metra, Ovidiu Chioncel, Andrew J. S. Coats, Giuseppe M. C. Rosano   +11 more
wiley   +1 more source

Peroxisome proliferator-activated receptors-alpha (PPAR-α) and chronic heart failure: Is there a reason to discuss the metabolic strategy of treatment?

Терапевтический архив, 2014
Despite improved prognosis in patients with heart failure (HF) treated with neurohumoral activation-suppressing drugs (such as angiotensin-converting enzyme inhibitors, angiotensin II receptor antagonists, Β-adrenergic receptor antagonists, aldosterone ...
I V Zhirov, A V Zaseeva, V P Masenko, S N Tereshchenko   +3 more
doaj  

Angiotensin II receptor antagonists: where do we stand?

, 2000
Losartan, the first angiotensin II receptor antagonist was introduced in 1994. Since then, five other antagonists have been launched for the management of hypertension.
Burnier, M., Maillard, M.
core  

The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists.

Anesthesia and Analgesia, 1999
S. Brabant, M. Bertrand, D. Eyraud, Pierre-Louis Darmon, P. Coriat   +4 more
semanticscholar   +1 more source